Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study (PREV-HAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04793568
Recruitment Status : Active, not recruiting
First Posted : March 11, 2021
Last Update Posted : February 16, 2022
Sponsor:
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:

PREV-HAP study is part of a larger project entitled 'Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia' (HAP2), funded by the European Union's H2020 research and innovation programme under grant agreement N°847782. HAP2 aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of HAP and develop precision medicine in infectious diseases. Its ambition is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, the aim is to propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis.

The main hypothesis of the PREV-HAP study is that human recombinant Interferon gamma 1b (rHuIFN-γ, Imukin) treatment can restore immunity in critically ill patients and prevent Hospital-Acquired Pneumonia.

The hypothesesis is that the in vivo investigations of the host-pathogens interactions can be used for the stratification of patients into high/low risk and responders/non-responders to host-targeted prevention of hospital-acquired infections.

The involvement of a state of critical-illness related immunosuppression in the susceptibility to hospital-acquired pneumonia is widely accepted, and an emerging trend is that the development of drugs for the treatment of this acquired immunosuppression will prevent infection and enhance outcomes of hospitalized patients.

It has been demonstrated that the productions of IFN-γ by immune cells are decreased in critically ill patients, and that these defects are associated with the susceptibility to HAP. rHuIFN-γ has neither been tested nor is recommended as adjunctive treatment of patients with HAP. Based on these specific factors identified in the host response, it is proposed in this study to use rHuIFN-γ as novel preventive approach for HAP.


Condition or disease Intervention/treatment Phase
Critically Ill Patients Drug: Recombinant Interferon gamma 1b (IMUKIN®) Drug: Recombinant Interferon gamma 1b placebo Phase 2

Detailed Description:

200 adult patients hospitalized in intensive care units, under mechanical ventilation in three European countries will be included in the trial, and will be randomized in 2 arms :

Arm 1 (rHu-IFNγ):

• Recombinant Interferon gamma 1b (IMUKIN®, from Clinigen®): 100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h),

Arm 2 (Placebo):

• Recombinant Interferon gamma 1b placebo: 5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 109 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study
Actual Study Start Date : March 29, 2021
Actual Primary Completion Date : November 7, 2021
Estimated Study Completion Date : June 2023


Arm Intervention/treatment
Experimental: Recombinant Interferon gamma 1b (IMUKIN®) Drug: Recombinant Interferon gamma 1b (IMUKIN®)
100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)

Placebo Comparator: Recombinant Interferon gamma 1b placebo Drug: Recombinant Interferon gamma 1b placebo
5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).




Primary Outcome Measures :
  1. To demonstrate the efficiency of rHuIFN-γ for the prevention of hospital-acquired pneumonia [ Time Frame: Day 28 ]
    Rate of the composite outcome at day 28 made of at least one item among the following: all cause mortality and/or hospital-acquired pneumonia


Secondary Outcome Measures :
  1. All-cause mortality [efficiency of rHu-IFN-γ, on pneumonia-associated morbidity and mortality reduction] [ Time Frame: Day 28 and Day 90 ]
    Rate of all-cause mortality at D28 and D90

  2. Rate of HAP [efficiency] [ Time Frame: Day 28 ]
    Rate of HAP at D28

  3. Bacterial ecology of the 1st episode of HAP [efficiency] [ Time Frame: Day 28 ]
    Bacterial ecology of the 1st episode of HAP (respiratory fluids)

  4. Rate of ventilator-associated tracheobronchitis [efficiency] [ Time Frame: Day 28 ]
    Rate of ventilator-associated tracheobronchitis at D28 defined as at least two of the following criteria: body temperature >38°C; leukocytosis>12000 cells/mL, leucopenia <4000 cells/mL, or purulent pulmonary secretions and a positive culture of a respiratory tract samples, without appearance of a new infiltrate or change in an existing infiltrate on chest radiography

  5. Occurence of Acute Respiratory Distress Syndrome [efficiency] [ Time Frame: Day 28 ]
    Acute Respiratory Distress Syndrome within 28 days after randomization

  6. Duration of antimicrobial therapy [efficiency] [ Time Frame: Day 28 ]
    Duration of antimicrobial therapy at D28, antibiotic free days at D28

  7. Duration of mechanical ventilation [efficiency] [ Time Frame: Day 90 ]
    Duration of mechanical ventilation at D90, mechanical ventilation free days at D90

  8. Duration of ICU hospitalization [efficiency] [ Time Frame: Day 90 ]
    Duration of ICU hospitalization at D90, Duration of hospitalization at D90.

  9. Rate of SAEs and SUSARs [tolerance] [ Time Frame: Day 15 ]
    Rate of serious adverse effects and suspected unexpected serious adverse reaction (SUSAR) at D15

  10. Rate of leukocytosis [tolerance] [ Time Frame: Day 15 ]
    Rate of leukocytosis at D15.

  11. Rate of neutropenia [tolerance] [ Time Frame: Day 15 ]
    Rate of neutropenia at D15.

  12. Rate of lymphopenia [tolerance] [ Time Frame: Day 15 ]
    Rate of lymphopenia at D15.

  13. Rate of thrombopenia [tolerance] [ Time Frame: Day 15 ]
    Rate of thrombopenia at D15.

  14. Rate of liver cytolysis [tolerance] [ Time Frame: Day 15 ]
    Rate of liver cytolysis (Increases in AST and/or ALT) at D15.

  15. Rate of pancreatitis [tolerance] [ Time Frame: Day 15 ]
    Rate of pancreatitis (Increase in Lipase) at D15.

  16. Rate of patients with episode of fever [tolerance] [ Time Frame: Day 15 ]
    Rate of patients with episode of fever (T° > 38.3°C)

  17. Rate of patients with episode of headache [tolerance] [ Time Frame: Day 15 ]
    Rate of patients with episode of headache

  18. Rate of patients with episode of nausea [tolerance] [ Time Frame: Day 15 ]
    Rate of patients with episode of nausea

  19. Rate of allergic reaction [tolerance] [ Time Frame: Day 15 ]
    Rate of major allergic reaction at D15 defined as systemic epidermic reaction, anaphylactic

  20. Incidence of injection site reaction [tolerance] [ Time Frame: Day 15 ]
    Occurence of injection site reaction at D15

  21. Rate of myalgia [tolerance] [ Time Frame: Day 15 ]
    Rate of myalgia at D15

  22. Rate of arthralgia [tolerance] [ Time Frame: Day 15 ]
    Rate of arthralgia at D15

  23. Rate of back pain [tolerance] [ Time Frame: Day 15 ]
    Rate of back pain at D15

  24. Economic efficiency of rHu-IFN-γ in the prevention of pneumonia [ Time Frame: Day 90 ]
    Economic endpoint at 3 months: Incremental cost effectiveness ratio (ICER). Analysis using QALYs (Quality-Adjusted Life-Years) as a measure of effectiveness. QALYs are a measure of effectiveness specifically designed for economic evaluations.

  25. To determine the suitability of rHu-IFN-γ from the patients' and relatives' perspectives using The Short Form (36) Health Survey [ Time Frame: Day 90 ]
    Changes in health-related quality of life (HRQoL) from one (M1) to three months (M3) after randomization measured with the Short Form (SF)-36 scale validated in French, Greek, and Spanish he SF-36 is a 36-item self-report questionnaire with 8 domains = Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health).The scores of each domain range from 0 to 100, a higher score indicating a better HRQoL.

  26. To determine the suitability of rHu-IFN-γ from the patients' and relatives' perspectives using the Hospital Anxiety and Depression scale (HADS) [ Time Frame: Day 90 ]

    Changes in anxiety and depression from M1 to M3 measured with the HADS scale validated in French, Greek, and Spanish. The HADS is a 14-item self-report questionnaire with 2 domains (anxietyand depression).

    The scores for anxiety and depression range from 0 (no symptoms) to 21 (significant number of symptoms).


  27. To determine the suitability of rHu-IFN-γ from the patients' and relatives' perspectives using Satisfaction With Life Scale (SWLS) [ Time Frame: Day 90 ]
    Changes in subjective well-being from M1 to M3 measured with the Satisfaction With Life Scale (SWLS) validated in French, Greek, and Spanish. The SWLS is a 5-item self-report questionnaire. The response scores to the five items are added together to provide a total score ranging from 5 (worst satisfaction level) to 35 (best level).

  28. To determine the acceptability of rHu-IFN-γ from the patients' and relatives' perspectives [ Time Frame: Day 90 ]
    Adaptation of the patients to their health state and its evolution from M1 to M3 using differential item functioning and response shift analyses for HRQoL, anxiety and depression. Change in the meaning of patients' self-evaluation between groups (DIF) and over time (response shift) will be inferred by the change in the items' parameters of the Partial Credit Models.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (18yr to 85yr).
  • Hospitalized in intensive care unit for less than 48 hours.
  • Receiving invasive mechanical ventilation at the time of inclusion.
  • One or more acute organ failure at the time of inclusion among: neurological (Glasgow coma scale <13 before sedation), hemodynamic (norepinephrine, epinephrine, or any other vasopressor at a dose of ≥ 0.1 μg per kilogram of body weight per minute or ≥0.5 mg per hour for at least 6 hours), respiratory (PaO2 / FiO2< 200) and/or renal (creatininemia > 2 fold higher than the basal value and/or oliguria < 0.5 mL/kg/hour for at less 12 hours).
  • Informed consent from a legal representative, or emergency procedure (when possible according to national regulation, see below). As is not possible to obtain the patient consent prior the inclusion (comatose patients), patient consent for the study continuation will be obtained as soon as deemed possible.
  • Person insured under a health insurance scheme.

Exclusion Criteria:

  • Pregnant women (serum or urine test), breastfeeding women
  • Patient under legal protection (incl. under guardianship or trusteeship)
  • Hypersensitivity to the active substance (interferon gamma-1b) or known hypersensitivity to related products, such as another interferon, or to any of the following excipients: Mannitol, Disodium succinate hexahydrate, Succinic acid, Polysorbate 20
  • Severe hepatic insufficiency ( Child Pugh score B or C)
  • Liver cytolysis with hepatic enzymes (AST and/or ALT) > 5N
  • Severe chronic renal insufficiency (MDRD Creatinine Clearance < 10 ml/min/1.73m2)
  • Immunosuppression (hematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, known infection Human immunodeficiency virus, concomitant use of any anti-graft rejection drug).
  • Coma after resuscitated cardiac arrest
  • Cervical spinal cord injury
  • Participation to a drug interventional study within 1 month prior to the inclusion
  • Hospital-acquired pneumonia before inclusion in the study during the current hospitalization.
  • Sustained hyperlactatemia > 5 mmol/L.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04793568


Locations
Show Show 18 study locations
Sponsors and Collaborators
Nantes University Hospital
Layout table for additonal information
Responsible Party: Nantes University Hospital
ClinicalTrials.gov Identifier: NCT04793568    
Other Study ID Numbers: RC20_0082
First Posted: March 11, 2021    Key Record Dates
Last Update Posted: February 16, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Healthcare-Associated Pneumonia
Critical Illness
Respiratory Tract Infections
Infections
Lung Diseases
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Cross Infection
Iatrogenic Disease
Interferons
Interferon-gamma
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents